Amgen Inc (AMGN) Q4 2025 Earnings Call Highlights: Blockbuster Growth and Strategic Challenges [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
Repatha Sales: Grew 36% year over year, surpassing $3 billion. EVENITY Sales: Increased 34% to $2.1 billion. Prolia Sales: $4.4 billion, a 1% increase year over year. UPLIZNA Sales: Increased 73% to $655 million. TEPEZZA Sales: Grew 3% to $1.9 billion. TAVNEOS Sales: $459 million, a 62% increase year over year. TEZSPIRE Sales: Grew 52% to nearly $1.5 billion. Otezla Sales: Increased 7% to nearly $2.3 billion. Innovative Oncology Portfolio: Grew 11% to $8.7 billion. Biosimilar Portfolio Sales: Increased 37% to $3 billion. Non-GAAP Operating Margin: 46% for the full year. Non-GAAP R&D Spending: Increased 22% to $7.2 billion. Free Cash Flow: $8.1 billion for the full year. Debt Retired: $6 billion in 2025. Non-GAAP Tax Rate: 15.9% for the full year. Capital Expenditures: $2.2 billion in 2025. Dividend Payments: $2.38 per share in Q4, a 6% increase from 2024. 2026 Revenue Outlook: $37.0 billion to $38.4 billion. 2026 Non-GAAP EPS Outlook: $21.60 to $23
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Argus from $360.00 to $400.00. They now have a "buy" rating on the stock.MarketBeat
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Guggenheim from $305.00 to $347.00. They now have a "neutral" rating on the stock.MarketBeat
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $285.00 to $295.00. They now have a "hold" rating on the stock.MarketBeat
- CVS Health to swap Amgen and Lilly's bone drugs with biosimilars in commercial formularies [Seeking Alpha]Seeking Alpha
- Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline” [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/3/26 - Beat
AMGN
Sec Filings
- 2/3/26 - Form 8-K
- 1/30/26 - Form 8-K
- 11/21/25 - Form 4
- AMGN's page on the SEC website